AccuGenomics is the exclusive license holder to a suite of patented technologies from the University of Toledo that enable advanced genomic testing applications. Amongst the technologies being developed and commercialized by AccuGenomics are the SNAQ™-SEQ spike-in standards for NGS that provide NGS-assay developers with powerful standardization tools that improve the detection of low abundance DNA or RNA targets. AccuGenomics partners with leading healthcare organizations in the development of these advanced genomic tests. We have several ongoing opportunities for partnerships which include a lung cancer risk test.
We are seeking additional co-development partnerships enabled by our SNAQ-SEQ technology in the areas of:
- Minimal Residual Disease (MRD) detection using NGS-based ctDNA assays
- Standardizing serial monitoring of ctDNA from cancer patients undergoing therapy
- Extraction and process spike-in standards
- RNASeq for Transcript Abundance
- Standards for single-cell analysis
AccuKit™ LCRT13: A set of 13 biomarkers predictive for Lung Cancer (Lung Cancer Risk Test) in high-risk patients based on age and smoking history.
Lung cancer remains the most prevalent cause of cancer death in the United States (160,000 deaths each year). A recent NIH-sponsored study determined that annual screening by chest CT scan reduces mortality from lung cancer by more than 20%. However, the annual cost of CT scan screening all 7 million individuals at risk for lung cancer due to age and smoking history exceeds $5 billion. The AccuGenomics Lung Cancer Risk Test promises to identify the individuals genetically pre-disposed to lung cancer so that they can be prioritized for screening. This will markedly reduce the cost of CT screening.
- Format: RNASeq NGS Panel (Bronchoscopy and matching blood samples)
- Status: Recruited 380 patient specimens. Seeking a co-development partner for validation and commercialization.
Craig, D.J., Morrison, T., Khuder, S.A., Crawford, E.L., Wu, L., Xu, J., Blomquist, T.M. and Willey, J.C., (2019). Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells. BMC Cancer, 19(1), p.1081.
Yeo, J., Morales, D.A., Chen, T., Crawford, E.L., Zhang, X., Blomquist, T.M., Levin, A.M., Massion, P.P., Arenberg, D.A., Midthun, D.E., Mazzone, P.J., Nathan, S.D., Wainz, R.J., Nana-Sinkam, P., Willey, P.F.S., Arend, T.J., Padda, K., Qiu, S., Federov, A., Hernandez, D.-A.R., Hammersley, J.R., Yoon, Y., Safi, F., Khuder, S.A. and Willey, J.C., (2018). RNAseq analysis of bronchial epithelial cells to identify COPD-associated genes and SNPs. BMC Pulmonary Medicine, 18(1), p.42.
Yeo, J., Crawford, E.L., Zhang, X., Khuder, S., Chen, T., Levin, A., Blomquist, T.M. and Willey, J.C., (2017). A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells. BMC Cancer, 17(1), p.301.
Crawford, E.L., Levin, A., Safi, F., Lu, M., Baugh, A., Zhang, X., Yeo, J., Khuder, S.A., Boulos, A.M., Nana-Sinkam, P., Massion, P.P., Arenberg, D.A., Midthun, D., Mazzone, P.J., Nathan, S.D., Wainz, R., Silvestri, G., Tita, J. and Willey, J.C., (2016). Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository. BMC Pulmonary Medicine, 16(1), p.16.
Kozodoy, N.; Crawford, E., Hammersley, J., Willey, J.C., (2016). Abstract: Accuracy of Self-Reporting in Diagnosis of COPD. AJRCCM Conference 2016; May 15, 2016; San Francisco, CA.
Crawford, E.L., Blomquist, T.M. and Willey, J.C., (2015). Abstract 4259: Conversion of the Lung Cancer Risk Test (LCRT) to a next generation sequencing (NGS) platform. Clinical Research (Excluding Clinical Trials). Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research.pp.4259–4259.
Blomquist, T., Crawford, E.L., Yeo, J., Zhang, X. and Willey, J.C., (2015). Control for stochastic sampling variation and qualitative sequencing error in next generation sequencing. Biomolecular Detection and Quantification, 5, pp.30–37.
Yeo, J., Zhang, X., Crawford, E.L. and Willey, J.C., (2014). Abstract 4156: Inter-individual variation in allele specific expression of catalase (CAT) in normal bronchial epithelial cells and association of putative cis-regulatory CAT SNP rs12807961 with lung cancer risk. Epidemiology. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research.pp.4156–4156.
Boulos, A; Lu, M; Nana-Sinkam, P; Massion, P; Levin, A; et al., (2014). MOLECULAR INSIGHTS INTO LUNG CANCER I: Safety Of Bronchoscopic Brush Biopsy In Subjects Recruited For Lung Cancer And COPD Risk Test Validation. American Journal of Respiratory and Critical Care Medicine; 189(1).
Blomquist, T.M., Crawford, E.L., Lovett, J.L., Yeo, J., Stanoszek, L.M., Levin, A., Li, J., Lu, M., Shi, L., Muldrew, K. and Willey, J.C., (2013). Targeted RNA-Sequencing with Competitive Multiplex-PCR Amplicon Libraries. PLoS ONE, 8(11), p.e79120.
Yeo, J., Crawford, E.L., Zyrek-Betts, J., Khuder, S.A., Austermiller, B. and Willey, J.C., (2012). Abstract 5541: Molecular diagnostic tests to augment cytomorphologic diagnosis of lung cancer. Clinical Research. Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research.pp.5541–5541.
Stanoszek, L.M., Crawford, E.L., Mann, H., Moore, M., Olivieri, T., Lu, M., Levin, A. and Willey, J.C., (2012). Abstract 5549: Normal bronchial epithelial cells (NBEC) sample RNA quality characteristics that will yield reliable measurement of lung cancer risk test. Clinical Research. Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research.pp.5549–5549.
Willey, J.C., (2011). Abstract 3168: An antioxidant and DNA repair gene expression pattern associated with lung cancer risk is also associated with COPD risk. Clinical Research. Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research.pp.3168–3168.
Blomquist, T.M., Crawford, E.L. and Willey, J.C., (2010). Cis-acting genetic variation at an E2F1/YY1 response site and putative p53 site is associated with altered allele-specific expression of ERCC5 (XPG) transcript in normal human bronchial epithelium. Carcinogenesis, 31(7), pp.1242–1250.
Willey, J.C., Blomquist, T., Kern, J.A., Massion, P.P., Nana-Sinkam, P., Jett, J.R., Kvale, P.A., Midthun, D.E., Johnson, C., Levin, A., Crawford, E.L., Lazaridis, Nick, Anders, J. and Austermiller, B., (2010). Multi-Institutional Trial Of A Lung Cancer Risk Test. C40. LUNG CANCER: PATHOBIOLOGY, STAGING, AND TREATMENT. American Thoracic Society 2010 International Conference, May 14-19, 2010; New Orleans. American Thoracic Society. pp. A4411–A4411.
Blomquist, T., Crawford, E.L., Mullins, D., Yoon, Y., Hernandez, D.-A., Khuder, S., Ruppel, P.L., Peters, E., Oldfield, D.J., Austermiller, B., Anders, J.C. and Willey, J.C., (2009). Pattern of Antioxidant and DNA Repair Gene Expression in Normal Airway Epithelium Associated with Lung Cancer Diagnosis. Cancer Research, 69(22), pp.8629–8635.